Constitutive Knock Out

Mrp1 Constitutive Knock Out Mouse Model

FVB Background

  • Model #
  • Genotype
  • Nomenclature
  • 1486-F
    FVB.129P2-Abcc1atm1Bor N12
  • 1486-M
    FVB.129P2-Abcc1atm1Bor N12
  • Carries a disruption of the Abcc1a (ATP-binding cassette, sub-family C (CFTR/MRP), member 1a) gene that encodes an ATP-dependent drug-extruding transporter formerly known as Mrp1
  • Abcc1a encodes ATP-dependent transport proteins for glutathione-, glucuronide-, or sulfate-conjugated substrates, including endogenous compounds such as steroids and leukotrienes as well as xenobiotics drugs
  • One of a family of ATP-binding cassette genes which encode multi-drug resistance proteins which confers resistance to a range of cytotoxic drugs
  • Exhibits normal fertility and viability but is deficient in functional MRP1 protein, leading to a 95% reduction in cellular transport of glutathione-conjugated substrates and decreased transport of leukotrienes C4, known inflammatory mediators
  • Exhibits an impaired inflammatory stimulus response and hypersensitivity to the anti-cancer drug, etoposide and vincristine
  • Useful for studying the role of ATP-dependent transporters in mediating inflammatory response and to test drug disposition
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Genetic Background:

FVB Background


The Mrp1 mouse was developed in the laboratory of Piet Borst at the Netherlands Cancer Institute. The model was created by targeting the Abcc1a gene in 129/Ola derived E14 ES cells and injecting the targeted cells into blastocysts. Resultant chimeras were backcrossed to FVB/N for six generations (N6). Taconic received stock in 1999. After additional backcrosses to FVB/NTac to N12, the line was embryo derived. Heterozygotes were intercrossed to generate homozygotes. The colony is maintained through incrossing of homozygous mice.


Wild type for Nnt mutation; carries Pde6brd1 mutation





Initial Publication:

Wijnholds J, Evers R, van Leusden MR, Mol CAAM, Zaman GJR, Mayer U, Beijnen JH, van der Valk M, Krimpenfort P, Borst P. (1997) Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein.; Nature Med, 3:1275-9.

Conditions of Use for Taconic Transgenic Models™
Taconic Transgenic Models™ (Models) are produced and distributed under rights to patents and intellectual property licensed from various institutions. Taconic sells the Models to purchasers, grants to each purchaser a right under Taconic's rights in such licensed patents and intellectual property to use the purchased Model in consideration of purchasers' acknowledgement of and agreement to the Terms and Conditions of Sale and the following terms of use:
  • Title to these Models and biological materials derived from them remains with Taconic Biosciences, Inc.
  • The Models will be used for research purposes only.
  • The Models will not be bred except to obtain embryos or fetuses required for research purposes
  • The Models and biological materials derived from them will not be distributed to third parties or used for commercial purposes.